Earlier this week, Daiichi Sankyo and AstraZeneca received approval in China for ENHERTU as the first HER2-directed antibody-drug conjugate for second-line treatment of HER2 positive metastatic ...

GSK is set to buy Rapt Therapeutics in a $2.2 billion deal. AstraZeneca agreed to a $630 million pact to secure remaining rights to armored CAR-T from AbelZeta. Bristol Myers Squibb signed a deal with ...

While Eli Lilly LLY is a market leader in the GLP-1 segment, thanks to its tirzepatide medicines Mounjaro (for diabetes) and ...

British finance minister Rachel Reeves will accompany Prime Minister Keir Starmer on his trip to China next week, ...

Daiichi Sankyo Co Ltd and AstraZeneca PLC on Thursday said Chinese regulators have approved their jointly developed drug Enhertu to treat gastric cancer. Enhertu is now cleared as a second-line ...

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an ...

Pharmaceutical stocks got a boost after President Trump said he would not impose tariffs on several European countries following his meeting with the NATO Secretary General over Greenland.

Despite guideline recommendations and improved access to care, individuals with hypertension are unlikely to measure their blood pressure at home as often as recommended, according to data from ...

While a majority of the therapies currently in development are life-long treatments, Genespire is taking a different approach ...

AstraZeneca is acquiring Modella AI to embed multimodal foundation models into oncology R&D and strengthen biomarker driven ...

The PSMA-targeted therapy market is expected to grow strongly, fueled by higher prostate cancer diagnosis rates, improved awareness of PSMA-based treatments, and an expanding clinical trial landscape ...

Astrazeneca plc is paying up to $630 million to acquire China rights to Abelzeta's Pharma Inc.’s C-CAR031 (AZD5851), an autologous glypican 3-targeting CAR T, securing global rights to develop, ...